ELANE

Summary: ELANE enhances GFI1-mediated transcriptional repression in the reported cellular assays.

Reason: Human ELANE constructs increase GFI1-dependent reporter repression in mouse NIH 3T3 cells, and ELANE knockdown increases AZU1 transcript abundance in human HL-60 cells. The latter assay uses AZU1 as a feedback readout rather than directly measuring autorepression of ELANE after its depletion. Reporter activity is retained by an author-numbered S173A catalytically inactive construct, separating the measured coregulatory effect from proteolysis. This experimentally supported context is retained without making it the principal protease function or claiming a direct DNA-binding activity.

Summary: The cited interaction concerns cleavage of a protease inhibitor, not binding to a protease partner.

Reason: GO:0002020 requires a protease or peptidase as the binding partner. The imported partner P08697 is human SERPINF2/alpha-2-antiplasmin. In the original study, purified human leukocyte elastase cleaves and inactivates plasma alpha-2-plasmin inhibitor; the inhibitor does not inhibit elastase amidolytic activity under the tested conditions. This is positive enzyme–substrate evidence but does not support this source-specific protease-binding assertion. The demonstrated proteolysis is retained through the catalytic annotation from the same paper; neither the interaction nor ELANE protease activity is rejected.

Summary: ELANE contributes to acute inflammatory host defence in a defined infection setting.

Reason: The literal PAINT assertion at PTN001546391 lies on the human lineage and is grounded in mouse Elane evidence. PMID:17878334 tests Spi6/Elane genetic backgrounds during Pseudomonas exposure; release of neutrophil protease activity and a narrow-dose human-NE supplementation experiment connect ELANE to the acute response. This is contextual inflammatory participation, not a claim of universally pro-inflammatory action or a human genetic experiment. The donor count and presence of target evidence elsewhere do not weaken the ancestral assertion.

Summary: ELANE supports stimulus-dependent leukocyte migration during inflammation.

Reason: The human target descends from the literal PTN001546391 IBD node. Its rat donor PMID:20860667 used BbCI, which inhibits elastase, cathepsin G and cathepsin L, so that experiment alone does not isolate ELANE. Independent Elane-deficient mouse evidence in PMID:15034066 supports a context-specific migration contribution during zymosan inflammation, with altered mediator production. Retain this broad contextual process without presenting the rat inhibitor as ELANE-selective or asserting a universal migration mechanism.

Summary: The orthology transfer is consistent with a contextual migration role.

Reason: D4A488 and ENSRNOP00000014981 resolve to rat Elane; the imported donor identity is preserved. The rat BbCI study supports altered inflammatory migration but cannot separate ELANE from the other inhibited proteases. Mouse Elane deficiency independently affects zymosan-elicited migration and mediator responses. Together these support retention as a non-core process, with species and stimulus limits, rather than an assertion that the rat experiment establishes an isolated human ELANE mechanism.

Summary: ELANE cleavage produces antibacterial thrombin-derived peptides in the reported experimental system.

Reason: Human neutrophil elastase directly digests human thrombin/prothrombin, generating fractions active against Escherichia coli. This establishes an enzymatic step in antibacterial-peptide production. The study also tests synthetic thrombin-derived peptides against Pseudomonas aeruginosa and in mice; those peptide effects must not be described as an ELANE perturbation experiment. This specific peptide-generation context is retained alongside the broader protease function. Raw GOA contexts distinguish interacting taxa 562 and 287, although the normal projection preserves one source row.

Summary: The study supports a context-dependent transcription corepressor role for ELANE.

Reason: GFI1-dependent reporters, promoter ChIP and protein associations support ELANE participation in a transcriptional coregulatory complex. GO:0003714 permits action through a DNA-binding transcription factor as part of a complex, and does not require the coregulator itself to bind DNA. The reporter experiments use transfected human constructs in mouse NIH 3T3 cells; human HL-60 knockdown provides a separate endogenous expression readout. The data do not establish a constitutive nuclear function of all processed enzyme preparations.

Summary: Human neutrophil elastase cleaves human kininogens through serine endopeptidase activity.

Reason: The recovered original identifies human neutrophil elastase and human plasma kininogens. Digestion, HPLC and peptide mass spectrometry demonstrate internal proteolytic fragmentation. Subsequent kallikrein assays measure reduced kinin release after elastase pretreatment, with elastatinal controls separating the two enzyme steps. Refine the broad endopeptidase term to GO:0004252, consistent with the independently established ELANE catalytic class. Enzyme purification is delegated to an earlier reference; its exact processed termini were not authenticated here.

Proposed replacements: serine-type endopeptidase activity

Summary: Purified human leukocyte elastase directly hydrolyzes internal bonds in plasma protein inhibitors.

Reason: The original Methods purify human leukocyte elastase from leukocyte granules, separate it from cathepsin G and characterize the preparation. Time-dependent cleavage of alpha-2-plasmin inhibitor and C1 inactivator is measured by electrophoresis and loss of inhibitory function. Serine-type endopeptidase activity is the established catalytic class of ELANE and is a verified is_a child of the imported endopeptidase term; the more specific term retains the positive experiment. Historical sequencing supports the serine-protease architecture but does not establish that every study used the same processed preparation.

Proposed replacements: serine-type endopeptidase activity

Summary: Human ELANE directly cleaves GSDMD in the reported biochemical experiments.

Reason: The study combines cleavage of FLAG-tagged human GSDMD in transfected HEK293T lysates with cleavage of bacterially produced His-SUMO human GSDMD, mass spectrometry and cleavage-site mutations. Human C268 cleavage and mouse V251 cleavage are separate results; mouse ELANE precursor activation by cathepsin C is also a distinct preparation. These experiments support internal peptide-bond hydrolysis by ELANE. The subsequent membrane-pore formation is performed by the released GSDMD fragment, not by ELANE. Detailed supplemental preparation information was not recovered from the attempted supplement routes.

Summary: ELANE has conserved serine-type endopeptidase activity.

Reason: The target sequence exactly matches the PAINT human leaf and inherits the GO:0004252 assertion at PTN001207468. The experimental descendants include human ELANE itself as well as related active proteases; this is legitimate experimental grounding, not circularity. Independent native-human active-site structure and human substrate cleavage support the chemistry. Historical mature preparations are not equated with the complete 267-residue precursor.

Summary: ELANE directly performs histone proteolysis in the source experiments.

Reason: Purified NE cleaves histones and chromogenic peptide substrates, while human-neutrophil experiments corroborate stimulus-associated histone processing. These observations support the established serine-type endopeptidase activity. The commercial enzyme preparation is not sequence-authenticated to a full precursor or a particular processed endpoint; GW311616A also inhibits PR3, so the combined biochemical and cellular evidence is used rather than unique inhibitor specificity.

Summary: Native human neutrophil elastase proteolyzes the bacterial MPO inhibitor SPIN.

Reason: The original Methods identify human purulent-sputum neutrophil elastase, catalogue SE563. Incubation with recombinant bacterial SPIN causes incomplete but detectable cleavage and loss of MPO inhibition; the effect is weaker than that of cathepsin G or PR3 and requires more elastase. Protease termination with PMSF and protection by Eap support an enzymatic mechanism. This directly supports the serine-type endopeptidase activity without equating the preparation to an unprocessed 267-residue precursor.

Summary: Recombinant human neutrophil elastase cleaves GSDMB in the reported substrate assays.

Reason: Human GSDMB-expressing HEK293T lysates are incubated with recombinant human NE, and a BAY-678-sensitive C-terminal fragment is assigned by mass spectrometry to cleavage at substrate residue M220. The separate p36 fragment is attributed to background caspase processing, rather than to NE. Ectopic NE also reduces the cytotoxicity of GSDMB N-terminal constructs, although the corresponding cellular cleavage fragments were not detected. The four splice forms studied are GSDMB substrates, not four ELANE products. These data establish protease activity but do not justify treating all gasdermin cleavage as pyroptosis activation.

Summary: The domain and mouse evidence agree with established human serine endopeptidase activity.

Reason: IPR001254 and IPR018114 map the trypsin-like protease domain and histidine active-site signature, while the exact mouse identifiers resolve to Elane. Domain membership alone would not establish an active enzyme, but native-human active-site evidence and direct proteolysis independently establish this activity. Preserve the imported composite mapping and the distinction between mature experimental enzyme and the official precursor.

Summary: Reactome explicitly places ELANE in an elastin-cleaving catalyst set.

Reason: R-HSA-1566962 reaches P08246 through catalystActivity 2514811, physical entity 2514800 and member 1602474. This is an enzyme role, not simply presence among reaction inputs. The curated elastin model is compatible with independently established ELANE serine proteolysis; the underlying elastin paper was not independently read in this consultation.

Summary: ELANE is the modeled protease in NOTCH2NLA cleavage.

Reason: R-HSA-9911236 identifies catalyst 9911491 and the ELANE-containing complex 9911480, with P08246 component 1602474. This catalyst path is distinct from the separate binding event. It supports the established enzyme activity in this curated substrate context; no new direct NOTCH2NLA experiment or autonomous signaling activity is inferred here.

Summary: The collagen VIII event contains an explicit ELANE catalyst.

Reason: The exact R-NUL-2482182 model follows catalyst 2482187 to P08246 entity 1602474. The unassigned event identifier is preserved and does not erase its explicitly identified human enzyme. The source is a curated reaction model, while native-human enzyme evidence independently supports the serine endopeptidase class.

Summary: Human ELANE is the catalyst in a cross-species fibrillin degradation model.

Reason: R-NUL-2514835 is labeled Bos taurus at the event level, but its catalyst 2482187 resolves to human P08246 entity 1602474. Preserve this substrate/event-species distinction; it is neither evidence of a wrong human gene nor proof of an intact human physiological assay. The modeled cleavage agrees with established ELANE serine endopeptidase activity.

Summary: ELANE occurs in the catalytic protease set for nidogen cleavage.

Reason: R-NUL-2533972 follows catalyst 2533962 through physical entity 2533968 to human ELANE member 1602474. The target is therefore represented as a catalyst, not merely a cleaved substrate. This curated substrate context is compatible with established enzyme activity; the cited nidogen originals were not independently examined here.

Summary: ELANE cleaves synthetic peptides derived from the PAI-1 reactive-site loop.

Reason: The original study tests synthetic fluorogenic PAI-1-derived peptides with purified human neutrophil elastase. It cites earlier work for cleavage of intact PAI-1 and explicitly reports different cleavage behavior of the peptide and native serpin. This supports the imported substrate-related interaction at the assayed peptide scope, without claiming a new intact PAI-1 complex or inferring a specialized binding function solely from the partner label.

Summary: The reported ELANE–CD40 interaction concerns proteolytic substrate engagement.

Reason: The original abstract reports CD40 loss from fixed human gingival fibroblasts, cell lysates and membranes after human leukocyte elastase treatment. Recovered Methods identify commercial human enzyme and CD40/CD40L assays. Retain the positive substrate-related binding assertion as non-core without claiming a stable receptor complex or purified binding affinity. Only selected original Methods and Discussion, together with the abstract, were recovered; complete Results and figure images were not inspected.

Summary: Human neutrophil elastase proteolyzes the urokinase receptor in the reported human-cell and purified-substrate assays.

Reason: The recovered original Methods identify elastase purified from human bone-marrow neutrophils and recombinant human CD87 residues Leu1–Arg281 with a C-terminal His tag. Experiments on U937 cells, primary blood monocytes and purified receptor distinguish elastase-dependent N-terminal D1 removal from cathepsin G-dependent C-terminal cleavage. Peptide mass spectrometry identifies elastase cleavage at Val85. Retain the substrate-related interaction without converting it into a stable receptor complex or transferring the separate cathepsin G cleavage pattern to ELANE. Selected original Methods and Results were read; no figure pixels or exact mature-enzyme termini were authenticated.

Summary: The paper includes direct human neutrophil elastase–alpha1-proteinase inhibitor complex experiments.

Reason: Although the crystallographic complex contains porcine pancreatic elastase, the original separately prepares and assays human neutrophil elastase complexes. Methods identify commercial HNE and a His-tagged, multiply modified alpha1-proteinase inhibitor; dissociation and susceptibility experiments include the HNE complex. These are positive interaction data for the human enzyme, so the porcine structure in the title is not evidence against the imported pair. Retain generic non-core binding with the engineered inhibitor and unresolved HNE processing boundaries; do not describe the porcine structure as a human ELANE structure.

Summary: PFAAP5 associates with the tested C-terminal ELANE construct and with ELANE in transfected-cell complexes.

Reason: A human bone-marrow two-hybrid screen recovers PFAAP5 with the author-numbered P110–H238 ELANE fragment but not P110–Q218. Reciprocal coimmunoprecipitation in mouse NIH 3T3 cells uses human expression constructs and an untagged control. These are positive interaction data with processing-dependent scope. The attempted native HL-60 immunoprecipitation was technically unsuccessful because the antibodies were unsuitable, rather than a negative interaction experiment. Generic binding is retained without inventing a specific partner-class function.

Summary: ELANE and GFI1 are recovered in the tested transcriptional protein association.

Reason: Coimmunoprecipitation and promoter ChIP in transfected NIH 3T3 cells support ELANE association with GFI1 in the presence of PFAAP5. These assays do not distinguish a direct binary interface from a bridged complex, and the native HL-60 complex was not successfully immunoprecipitated. The measured association is retained as generic non-core binding, with the separately demonstrated reporter corepression preserved in its own annotation.

Summary: Human neutrophil elastase directly cleaves the assayed mouse collagen XVII fragment.

Reason: The imported mouse Q07563 partner is consistent with the purified recombinant mBP180ABC substrate containing NC14A and part of C13. Highly purified human NE cleaves this fragment, with time-zero and no-enzyme controls and mass-spectrometric product analysis. Mouse wild-type versus Elane-null neutrophil supernatants provide separate corroboration. The paper also assays native human collagen XVII, but that does not replace the literal mouse partner in this source. Retain the substrate-related binding claim without inventing an additional collagen-binding function or a stable intact-protein complex.

Summary: ELANE directly binds the synthetic, refolded Agaphelin inhibitor.

Reason: Surface plasmon resonance measures elastase binding to immobilized synthetic Agaphelin with a mock-coupled surface control, alongside concentration-dependent inhibition of elastase activity. This is positive physical interaction evidence for the imported mosquito inhibitor. The article describes the mature sequence as 54 residues in one passage and the synthesized/refolded material as 58 residues in Methods; those descriptions are not silently reconciled to an authenticated natural insert. The inhibitor also acts on other proteases, so its cellular phenotypes are not uniquely attributable to ELANE. Generic non-core binding is retained.

Summary: Human neutrophil elastase cleaves a synthetic SARS-CoV-2 spike junction peptide.

Reason: The experiment uses sputum-derived human NE and a synthetic peptide spanning spike residues 678–691, with HPLC and mass-spectrometric identification of cleavage adjacent to the polybasic region. The authors explicitly leave intact homotrimer processing and post-translational modification effects for future work. This supports the imported substrate-related interaction at the peptide scope, without claiming whole-spike affinity, viral entry activity or a new physiological receptor complex.

Summary: The U2OS AP–MS network contains an exact ELANE–SERPINA1 interaction record.

Reason: The published AP–MS network records ELANE as bait and SERPINA1 as prey, joined by edge 630404. The main Methods use C-terminal HA–Flag-tagged ORFeome constructs expressed in human U2OS cells, affinity purification and tandem mass spectrometry with CompPASS filtering. This supports a screen-specific physical association or co-complex, without establishing purified binary contact, a native neutrophil complex or a particular processed ELANE chain. The paper reports clone sequence validation globally, but the precise target insert was not independently authenticated. Its separate imaging and SEC modalities are not treated as pair-specific corroboration.

Summary: Extracellular localization is conserved and supported for released ELANE.

Reason: The literal extracellular-region IBD at PTN001207468 is on the target ancestry and has experimental protease descendants, including human ELANE. Direct human-neutrophil and NET studies support extracellular release. This identifies a physiological pool without excluding azurophilic storage or transient cytosolic and nuclear pools.

Summary: ELANE has a supported released extracellular pool.

Reason: The cited paper reports antibacterial thrombin-fragment production using human NE and neutrophil material, but its description of activated supernatants differs from the extract-based preparation in Methods; this is not a clean independent protein-localization experiment. A separate human-neutrophil study detects a released soluble ELANE activity fraction alongside a larger cell-associated pool. The established extracellular localization is therefore retained with that explicit independent support, without relabeling the original extract preparation as a purified secretome.

Summary: ELANE is explicitly detected in the soluble human sputum proteome.

Reason: The original reports neutrophil elastase among proteins identified by LC–MS/MS in cystic-fibrosis sputum. Methods remove intact cells, cellular debris and insoluble material before analysis and search the spectra against human and bacterial protein databases. This supports an extracellular ELANE pool in the sampled inflammatory airway material. The immunofluorescence experiments target MPO, Hex A and paucimannose rather than ELANE, so they are not claimed as independent ELANE localization images. Supplemental target-table cells and figure pixels were not independently inspected.

Summary: Extracellular localization is biologically supported despite current rule-version uncertainty.

Reason: The saved current ARBA00027128 output includes extracellular region, but none of its 280 complete condition sets matches the current target record under the literal predicate replay. The historical rule version that produced this imported assertion was not recovered. This reproducibility limit does not contradict the independently demonstrated extracellular ELANE pool, so retain the location without claiming that the current rule premises reproduce this source row.

Summary: The source supports released extracellular elastase as well as a separately measured cell-bound pool.

Reason: The paper describes release of neutrophil proteases during activation and detects a small soluble activity fraction from partially activated human neutrophils. Most activity in the reported cell preparations remains cell-associated after washing. Extracellular-space localization is retained for the released fraction; cell-surface-bound enzyme is represented separately and is not conflated with freely extracellular protein.

Summary: Elastin-cleaving ELANE is modeled in the extracellular region.

Reason: R-HSA-1566962 links its catalyst set to extracellular P08246 entity 1602474. The modeled compartment agrees with independent human ELANE release evidence; this review does not relabel the model as a newly inspected primary assay or require exclusive extracellular residence.

Summary: Extracellular ELANE is represented in pro-MMP1 activation.

Reason: R-HSA-1592316 follows catalyst 1602460 through protease set 1602468 to extracellular ELANE 1602474. The model separates initial proteolysis from subsequent MMP autolytic completion. The modeled compartment agrees with independent human ELANE release evidence; this review does not relabel the model as a newly inspected primary assay or require exclusive extracellular residence.

Summary: Extracellular ELANE is represented in pro-MMP8 activation.

Reason: R-HSA-1592398 follows catalyst 2127618 through protease set 2127623 to extracellular ELANE 1602474. The modeled compartment agrees with independent human ELANE release evidence; this review does not relabel the model as a newly inspected primary assay or require exclusive extracellular residence.

Summary: Specific-granule release places an ELANE pool extracellularly.

Reason: R-HSA-6798749 has ELANE in the specific-granule input set and in output set 6806312 as extracellular entity 1602474. This is a transported cargo path, not evidence that ELANE catalyzes exocytosis. The modeled compartment agrees with independent human ELANE release evidence; this review does not relabel the model as a newly inspected primary assay or require exclusive extracellular residence.

Summary: Azurophil-granule release places ELANE extracellularly.

Reason: R-HSA-6798751 connects luminal ELANE in the input set to extracellular entity 1602474 in output set 6806184. ELANE is cargo in this event, not the exocytosis catalyst. The modeled compartment agrees with independent human ELANE release evidence; this review does not relabel the model as a newly inspected primary assay or require exclusive extracellular residence.

Summary: The bacterial-association model contains extracellular ELANE.

Reason: R-HSA-6813659 includes P08246 in input set 6813639 and the output bacterial complex 6813664. This is a physical participant path; it does not independently establish a catalytic step or a new binding subtype. The modeled compartment agrees with independent human ELANE release evidence; this review does not relabel the model as a newly inspected primary assay or require exclusive extracellular residence.

Summary: ELANE is extracellular in the NOTCH2NLA association event.

Reason: R-HSA-9911230 places extracellular ELANE entity 1602474 in its input and ELANE-containing output complex 9911480. Association is distinguished from the separate catalytic cleavage event. The modeled compartment agrees with independent human ELANE release evidence; this review does not relabel the model as a newly inspected primary assay or require exclusive extracellular residence.

Summary: ELANE is extracellular in the modeled NOTCH2NLA cleavage complex.

Reason: R-HSA-9911236 contains extracellular ELANE 1602474 within catalyst complex 9911480 and releases it as an output. The modeled compartment agrees with independent human ELANE release evidence; this review does not relabel the model as a newly inspected primary assay or require exclusive extracellular residence.

Summary: The collagen VIII model places ELANE extracellularly.

Reason: R-NUL-2482182 identifies human P08246 entity 1602474 in the extracellular catalyst path. The modeled compartment agrees with independent human ELANE release evidence; this review does not relabel the model as a newly inspected primary assay or require exclusive extracellular residence.

Summary: The fibrillin model places its human ELANE catalyst extracellularly.

Reason: R-NUL-2514835 is a Bos taurus event with an explicitly human P08246 catalyst entity 1602474. Event species and enzyme identity must remain distinct. The modeled compartment agrees with independent human ELANE release evidence; this review does not relabel the model as a newly inspected primary assay or require exclusive extracellular residence.

Summary: The nidogen model includes an extracellular ELANE catalyst.

Reason: R-NUL-2533972 reaches extracellular P08246 entity 1602474 through catalyst 2533962 and protease set 2533968. The modeled compartment agrees with independent human ELANE release evidence; this review does not relabel the model as a newly inspected primary assay or require exclusive extracellular residence.

Summary: Endogenous ELANE reaches the nucleus during the tested human-neutrophil activation response.

Reason: Imaging and fractionation show redistribution from granules to nuclei before NET release after stimulation. This is an endogenous, time-dependent localization in human neutrophils, not a constitutive nuclear-residence claim. Histone cleavage supplies functional context; the precise import or granule-escape mechanism is not resolved by these observations.

Summary: Human neutrophil ELANE translocates to the nucleus during the studied NET response.

Reason: The study follows endogenous ELANE through a transient cytosolic pool to the nucleus after PMA or Candida stimulation. Control, MPO-deficient and CGD donor comparisons distinguish this pathway from granule retention. This supports conditional nuclear localization, with no implication that all ELANE is constitutively nuclear.

Summary: Activated neutrophils can contain nuclear ELANE.

Reason: SL-0191 maps to nucleus. Independent endogenous human-neutrophil imaging and fractionation show ELANE moving from granules into nuclei during NET formation. This is a stimulus-dependent proteolytic pool, not a claim of constitutive nuclear residence or an inference from transfection alone.

Summary: The broad cytoplasmic annotation can be refined to the independently resolved cytosolic ELANE pool.

Reason: The cited study shows granular and nuclear-envelope distribution of transfected wild-type ELANE, with increased nuclear accumulation of a glycosylation mutant; that localization assay does not itself isolate cytosol. Independent human-neutrophil fractionation in PMID:25066128 resolves a transient soluble cytosolic pool during activation after granules are removed by ultracentrifugation. GO:0005829 names that supported cytoplasmic compartment and is part_of GO:0005737, not an is_a child. The refinement does not re-label the original transfection experiment as a cytosol assay or imply constitutive cytosolic residence.

Proposed replacements: cytosol

Summary: The supported cytoplasmic ELANE pool can be specified as cytosol.

Reason: The exact Q3UP87/ENSMUSP00000038925 donor resolves to mouse Elane. Its source uses operational cytosolic fractionation during bacterial activation; independent human-neutrophil fractionation in PMID:25066128 separates a transient soluble ELANE pool from granules. GO:0005829 is part_of GO:0005737, not an is_a child. This refinement preserves the original mouse transfer and does not imply constitutive or exclusive cytosolic localization.

Proposed replacements: cytosol

Summary: The lysosomal storage compartment is specifically an azurophil granule.

Reason: The SL-0158 mapping is consistent with a lysosomal compartment, but marker-resolved human neutrophil fractionation and imaging identify azurophilic granules. GO:0042582 is an is_a descendant of lysosome. The broader granule term is appropriate because observed ELANE distributions include membrane-associated, luminal and mixed patterns; this does not assert that every preparation is exclusively luminal.

Proposed replacements: azurophil granule

Summary: The gasdermin-cleaving ELANE pool is cytosolic.

Reason: R-HSA-9710106 explicitly links catalyst 9710078 to cytosolic ELANE entity 9710109. Human-neutrophil fractionation independently supports a soluble cytosolic pool, and the owner-inspected PMID:29539421 reports cytosolic ELANE during aging or bacterial exposure. This is a target enzyme location, not a compartment inferred solely from its GSDMD substrate.

Summary: ELANE directly performs proteolysis.

Reason: The literal proteolysis assertion at PTN001207468 is inherited by the human target, with direct human ELANE and PRTN3 experimental grounding. Native-human substrate cleavage independently demonstrates the process. Retain the conserved catalytic process without treating self-donor evidence as circular or requiring every descendant to share every substrate.

Summary: The source supports proteolysis by neutrophil granule enzymes, including ELANE.

Reason: The study combines human granule-enzyme purification and activity measurements with bacterial-protein digestion in human neutrophils and mouse genetic experiments. Its human mixed-protease inhibitor experiments are not selective ELANE knockouts, and the infection experiments use mice. These preparation and attribution limits do not undermine the established proteolytic function; the imported acts_upstream_of_or_within qualifier remains unchanged.

Summary: Human neutrophil elastase directly cleaves human thrombin and prothrombin.

Reason: The original study measures time-dependent substrate fragmentation and identifies antibacterial C-terminal thrombin-derived products using fractionation and mass spectrometry. This is direct proteolysis by ELANE. It is distinct from downstream membrane damage or mouse protection caused by added synthetic peptides.

Summary: The domain mapping agrees with direct ELANE proteolysis.

Reason: IPR001254 and IPR018114 provide the trypsin-like domain and active-site mapping. Independent human ELANE cleavage assays establish actual proteolysis, so this decision does not infer activity merely from a retained fold or signature.

Summary: Acute C5a-evoked calcium signaling does not by itself establish steady-state calcium homeostasis.

Reason: The accessible abstract reports suppression of C5a-stimulated intracellular calcium influx. GO:0006874 concerns maintenance of a steady intracellular calcium level, a different claim. Original methods and time courses were unavailable, so the extent of homeostatic evidence cannot be resolved. Retain UNDECIDED without declaring the imported NAS assertion false.

Summary: ELANE is associated with stimulus-specific phagocytic function.

Reason: The target inherits the literal phagocytosis IBD at PTN001546391. The mouse source PMID:15034066 reports impaired zymosan uptake in vivo after correcting for fewer infiltrating leukocytes, but no comparable defect for in-vitro zymosan or in-vivo E. coli uptake. The current experimental donor relation is acts_upstream_of_or_within, whereas the imported human qualifier is involved_in; preserve both records rather than silently equating them. Retain this existing contextual claim without asserting that ELANE is a general engulfment machine or that the perturbation alone resolves its precise step.

Summary: Purified human elastase directly binds heparin in the reported surface-plasmon-resonance assay.

Reason: Elastase is purified from human buffy-coat neutrophil granules, with reported mass-spectrometric identity confirmation, and tested against heparin by surface plasmon resonance. This directly supports heparin binding. The authors use this as a model for association with an anionic granule matrix; the experiment does not identify every physiological glycosaminoglycan partner or establish a separate principal molecular function.

Summary: The measured peptidase activity is the established serine-type endopeptidase activity of ELANE.

Reason: Purified-enzyme activity measurements and the granule proteolysis context support the broad imported claim. ELANE has a verified serine-protease active site and internal-bond cleavage, supporting the more specific GO:0004252 through the endopeptidase is_a branch. Mouse knockout and human mixed-inhibitor results are kept distinct from the purified-enzyme assay.

Proposed replacements: serine-type endopeptidase activity

Summary: The measured human ELANE peptidase activity is more specifically serine-type endopeptidase activity.

Reason: Human neutrophil elastase cleaves human thrombin/prothrombin into smaller products in the original assay. The established ELANE serine-protease catalytic class and internal-bond cleavage justify GO:0004252, which lies under endopeptidase activity and peptidase activity through verified is_a edges. The normal source qualifier and citation remain unchanged.

Proposed replacements: serine-type endopeptidase activity

Summary: The broad serine-peptidase activity can be specified as endopeptidase activity.

Reason: The complete current ARBA00027399 condition set18 matches the target FunFam and mammalian lineage. Its broad GO:0008236 output is correct, while native-human active-site evidence and cleavage of internal protein bonds support the is_a descendant GO:0004252. The refinement concerns reaction type, not an inferred new substrate specificity.

Proposed replacements: serine-type endopeptidase activity

Summary: The published abstract describes a UVA-associated fibroblast protease response, but the ELANE-specific experimental assignment cannot be independently verified from the accessible material.

Reason: The abstract of PMID:11928814 reports neutrophil-elastase immunoreactivity in fibroblast-like cells from sun-exposed skin and increased elastase-like activity after UVA, with no significant change after UVB. It also attributes the elastase-like activity to at least two enzymes. The complete original methods, inhibitor discrimination and experimental results were not accessible through the publisher, the institutional repository or the author-publication listing. The official GO:0009411 definition includes changes in enzyme production, so these observations are not dismissed merely as a stress-induced abundance change. However, the accessible abstract alone does not resolve how the UVA-induced activity was assigned specifically to ELANE rather than another elastolytic enzyme. Retain UNDECIDED pending the original experiments; no misattribution, negative result or annotation error is asserted.

Summary: Catalytically active ELANE is present at the surface of the tested human neutrophils.

Reason: Freshly purified blood neutrophils hydrolyze a selective ELANE substrate. Activity remains after washing, has the expected HPLC cleavage products, and is suppressed by the ELANE-directed inhibitor EPI-HNE4. Salt-release and cell-free-supernatant controls distinguish the surface-associated pool from released enzyme. This supports the actual external cell-associated localization without a transmembrane-protein claim.

Summary: ELANE participates in the experimentally assembled GFI1-associated transcription repressor complex.

Reason: Tagged protein associations, p21 promoter ChIP and GFI1-dependent reporter repression support a complex with transcription-repressing activity. ChIP requires the ELANE C-terminal segment that supports PFAAP5 association in this setup. The experiments use ectopic human constructs in mouse NIH 3T3 cells; they do not establish the stoichiometry or constitutive abundance of a native human complex. This positive, specialized context is retained.

Summary: ELANE engages and cleaves recombinant human G-CSF as a proteolytic substrate.

Reason: The recovered original directly incubates commercial human neutrophil elastase with recombinant human G-CSF and detects cleavage by gel analysis. G-CSF-dependent proliferation is reduced, while GM-CSF and SCF are comparatively spared. Retain cytokine binding at this catalytic substrate-engagement scope, not as a cytokine-receptor or stable signaling-complex function. The authors acknowledge possible minor contaminants in the neutrophil preparation and report replication with a second commercial preparation; exact enzyme termini and a binding affinity were not established.

Summary: ELANE performs extracellular-matrix cleavage steps.

Reason: The pathway R-HSA-1474228 reaches ELANE through its fibrillin-degradation event and explicit catalyst2482187, ending at P08246 entity1602474. Thus the target does some of the proteolytic work rather than merely being a matrix substrate or necessary bystander. Retain the process with the curated substrate/event-species boundaries; the pathway summary alone is not the evidence for target participation.

Summary: The secretory-granule localization can be specified as azurophil granule.

Reason: The cited study purifies ELANE from human neutrophil granules. Independent marker-resolved fractionation and imaging in PMID:20974816 and PMID:25066128 place it in azurophilic granules. GO:0042582 is a verified is_a child of secretory granule. This target-specific refinement does not claim that the 2002 preparation alone resolves every granule subtype.

Proposed replacements: azurophil granule

Summary: ELANE directly breaks down the native protein configuration of human kininogens.

Reason: Kininogen fragmentation by the human enzyme is direct participation in protein catabolism. The observed loss of subsequent kallikrein-dependent kinin release supports disruption of the substrate protein rather than merely enzyme binding. GO:0030163 includes breakdown of the native protein configuration without requiring complete degradation to amino acids. This existing broad catabolic annotation is retained; no new kinin-pathway or systemic anti-inflammatory claim is inferred.

Summary: ELANE is detected in human extracellular-matrix-enriched tissue preparations.

Reason: Additional file 2 lists ELANE/P08246 in the complete dataset and matrisome subset at Excel row 210, with 18 distinct peptides overall. The sequential extraction protocol depletes intracellular fractions and retains an insoluble ECM-enriched fraction. ELANE is detected in all 5 colon-tumor samples, 3 of 5 liver-metastasis samples and both normal-liver pools; the 4 normal-colon samples have no reported signal. These are sample counts, including repeated tissue pieces, rather than independent-patient counts. The positive human proteomic evidence supports retaining the ECM localization as contextual and non-core. Classification as a matrisome-associated ECM regulator does not establish a structural matrix function, exclusive residence or the active processing state, and the zero entries do not establish universal biological absence.

Summary: ELANE is reproducibly detected in ECM-enriched human bone-marrow preparations.

Reason: The original Methods and supplementary Methods describe sequential removal of cytosolic, nuclear, membrane and cytoskeletal proteins from human marrow aspirate pellets. Supplementary Table 3A row 98 identifies ELANE/P08246, with 16 distinct peptides overall and positive spectra in all 26 samples: 10 healthy donors, 3 MGUS, 7 newly diagnosed myeloma and 6 relapsed myeloma. Table 2 row 4 and Results explicitly place ELANE in all 4 groups. This supports retaining the observed ECM association as non-core. The source classifies ELANE as an ECM regulator, and the enrichment procedure does not establish exclusive matrix residence, a structural scaffold role, proteolytic activity in these samples or a particular processed product.

Summary: ELANE-mediated histone cleavage promotes chromatin decondensation in the tested systems.

Reason: Purified-enzyme and cellular evidence links histone proteolysis to nuclear enlargement and chromatin decondensation. Current GO:0031452 explicitly includes chromatin decondensation and decompaction as exact synonyms. The positive annotation is therefore retained without requiring a separate transcriptional-silencing or histone-modification mechanism, and without claiming that every NET stimulus depends on ELANE.

Summary: ELANE reduces CD40-dependent chemokine production in the reported fibroblast context.

Reason: The source reports reduced IL-8 and MCP-1 production after elastase treatment of human gingival fibroblasts stimulated through CD40L, while the IL-1alpha response remains. Proteolytic CD40 loss provides a source-specific mechanism for this contextual negative regulation. Retain the broad chemokine claim as non-core; it is not a claim of general suppression across inflammatory stimuli or cell types. Complete original Results remain unavailable.

Summary: ELANE reduces IL-8 production downstream of CD40L in human gingival fibroblasts.

Reason: The reported decrease in CD40L-stimulated IL-8, with a preserved IL-1alpha response, supports this existing negative-regulatory annotation. Its direction is specific to receptor cleavage in the studied cells and is compatible with positive IL-8 responses in other contexts. Retain it as non-core, with selected original access rather than a complete Methods/Results or figure-pixel claim.

Summary: Human neutrophil elastase induces IL-8 production in the reported A549-cell assay.

Reason: The authentic abstract reports IL-8 protein and mRNA responses in human A549 cells exposed to human neutrophil elastase, with suppression by an elastase inhibitor. This directly supports the existing contextual positive-regulation claim, which is retained as non-core. The operative original body could not be recovered, so preparation details and complete controls remain unresolved; this source is not used to assert a universal inflammatory direction.

Summary: The rule supports an azurophil-granule luminal ELANE pool.

Reason: Current ARBA00090615 condition set1 matches the target FunFam and Haplorrhini lineage. Its luminal output agrees with curated granule-release models and human evidence that includes luminal ELANE. This does not exclude membrane-associated or mixed granule distributions, nor replace the independently supported broader granule location with an exclusive lumen claim.

Summary: ELANE is modeled as azurophil-granule luminal cargo.

Reason: R-HSA-6798751 has P08246 entity6799238 in luminal input set6798742, followed by release into the extracellular output. The literal input compartment supports a luminal pool. It does not make ELANE an exocytosis catalyst or require all stored enzyme to occupy the same intragranular microdomain.

Summary: Retain the additional specific-granule luminal pool recorded by Reactome.

Reason: R-HSA-6798749 contains P08246 entity6800918 in specific-granule input set6799354 and an extracellular output. GO:0035580 explicitly permits elastase in this compartment, so dominant azurophilic storage is not grounds to declare this model false. The source is a curated proteomic granule assignment whose cited original was not independently read here. Retain it as an additional non-core compartment, without claiming exclusive residence or that ELANE drives exocytosis.

Summary: ELANE is localized to human neutrophil azurophilic granules.

Reason: Marker-resolved granule fractionation and resting-cell localization support this compartment. Stimulated redistribution to the nucleus is compatible with the resting granular pool. The evidence does not imply a single uniform granule topology or a demonstrated membrane-escape mechanism.

Summary: ELANE occupies azurophilic granules in the studied human neutrophils.

Reason: Purified granule fractions and immunogold observations identify ELANE in azurophilic granules. The original reports membrane-associated, luminal and mixed patterns in different granules. The broad compartment annotation accommodates that heterogeneity rather than imposing a uniform membrane or lumen-only topology.

Summary: Human neutrophil elastase directly reduces bacterial survival in the ecotin study.

Reason: The recovered Methods use human neutrophil elastase from Elastin Products Company for bacterial killing, distinct from the preparation used for kinetic assays. Colony counts compare E. coli exposed to elastase with buffer controls and show protection by bacterial ecotin. These are direct antibacterial-effector experiments, not solely a host knockout or abundance association. Retain defense response to bacterium, while leaving the decisive periplasmic substrate unidentified and avoiding an inference that every bacterial species is equally susceptible.

Summary: The source reports MAP-kinase activation downstream of elastase exposure.

Reason: The abstract describes p38 and ERK activation in the same A549-cell system. Pharmacological results distinguish their contributions to IL-8 production: p38 inhibition affects that output, whereas ERK inhibition does not. Retain the existing NAS positive-regulatory context as non-core. This does not assign kinase activity to ELANE or identify a direct kinase substrate, and the complete original experiments were unavailable.

Summary: The secretory lysosomal compartment can be identified as an azurophil granule.

Reason: SL-0543 supplies the broad cytolytic-granule mapping. Its definition gives cytotoxic lymphocytes as examples, not an exclusive taxon or cell-type restriction. Independent human neutrophil fractionation and imaging specifically resolve ELANE in azurophilic granules. Replace the broad functional granule category with GO:0042582 as a compartment clarification; this is not an is_a refinement of cytolytic granule and does not assert that the original mapping is biologically impossible.

Proposed replacements: azurophil granule

Summary: ELANE has a supported phagocytic-vesicle pool.

Reason: SL-0206 maps to phagocytic vesicle, and the official target record attributes phagosomal localization after bacterial phagocytosis to PMID:10947984. That source remains abstract-only in the owner access record, so no uninspected trafficking Methods are claimed. The established granule-delivery and antimicrobial protease context supports retaining the curated compartment; nuclear, cytosolic and extracellular pools do not contradict it.

Summary: Elastase increases airway smooth-muscle cell proliferation in the reported culture system.

Reason: The authentic abstract identifies human airway smooth-muscle cells and human neutrophil-derived elastase. Increased cell counts and a larger S-phase fraction support proliferation rather than increased cell size; ERK and cyclin-D1 measurements provide downstream context. Retain the existing positive-regulatory annotation as non-core. Original Methods and complete controls were not recovered, and no direct ELANE kinase activity, exact mature preparation or general in vivo remodeling effect is asserted.

Summary: Retain the reported contextual suppression of neutrophil inflammatory responses.

Reason: The abstract describes inhibition of C5a-driven degranulation and chemotaxis by purified human leukocyte elastase and proposes inflammatory down-regulation. Retain this existing NAS context as non-core, not universal anti-inflammatory benefit or demonstrated clinical resolution. No original-body access or specific substrate-cleavage mechanism is claimed.

Summary: Purified human leukocyte elastase suppresses C5a-directed chemotaxis in the reported assay.

Reason: The abstract explicitly identifies reduced C5a-dependent chemotaxis after purified human leukocyte elastase. It separately reports preserved FMLP, IL-8, LTB4 and PAF responses in the lysate/supernatant experiments and summarizes the purified-enzyme effect as selective. Retain this contextual claim as non-core while leaving the exact matched control layout, doses, processed-enzyme identity and affected substrate unresolved; neither C5a nor its receptor is asserted to be cleaved.

Summary: ELANE is detected in a healthy-human urinary-exosome-enriched preparation.

Reason: The study-linked NHLBI urinary-exosome database records historical ELA2/NP_001963 with 1 peptide under reference 2, the Gonzales et al. 2009 study. The official P08246 record lists ELA2 and NP_001963.1, establishing the target identity. Operative Methods describe pooled urine from 8 healthy adults, differential centrifugation and a DTT treatment to reduce uromodulin entrapment before LC-MS/MS; the paper distinguishes unambiguous protein identifications from its larger ambiguous list. Retain this positive fraction-proteomics localization as non-core, without assuming that a single peptide is false. The inspected evidence does not establish ELANE-specific vesicle topology, endosomal biogenesis, selective cargo loading, catalytic activity or a particular processing state.

Summary: ELANE-specific detection in the EPS-urine exosome dataset remains unverified.

Reason: The genuine original describes exosome-enriched pools from 12 low-grade prostate-cancer patients and 12 biopsy-negative controls, processed by differential ultracentrifugation with a DTT/sucrose wash and duplicate LC-MS/MS. The ELANE-specific protein and peptide assignment is delegated to Supplemental Table 2, which was not recovered as a valid workbook. Saved PMC/EuropePMC attempts and a bounded attempt at the publisher-confirmed Table S2 filename returned HTML or error payloads. The accessible main text supports the experimental design but cannot resolve this exact target record. Keep the assertion undecided rather than infer absence, misidentification or contamination; the authors’ general discussion of soluble and blood/immune contributions is not a demonstrated ELANE artifact.

Summary: ELANE can activate gasdermin in a context-dependent death and inflammatory pathway.

Reason: R-HSA-5620971 reaches ELANE through the explicit GSDMD-cleavage catalyst in R-HSA-9710106. The owner-inspected PMID:29539421 includes direct cleavage of human GSDMD and site testing, so ELANE performs an activation step rather than merely being required for an outcome. Current GO:0070269 denotes a gasdermin-dependent inflammatory response, not every lytic death. Retain this contextual pathway assignment without claiming that the inspected study measured ELANE-dependent IL-1beta/IL-18 production, that ELANE forms the pore, or that its net inflammatory effect is universally positive.

Summary: ELANE can contribute catalytic work to neutrophil antimicrobial defense by disabling SPIN.

Reason: Purified human NE partially degrades the S. aureus MPO inhibitor SPIN and relieves its inhibitory activity, while the same study independently demonstrates the effects of SPIN integrity on MPO-dependent bacterial killing and intraphagosomal bacterial GFP bleaching. This supplies a mechanistic antimicrobial contribution through proteolysis of an immune-evasion factor. The combined experiments do not isolate an ELANE-specific killing effect in intact neutrophils, and NE is less effective than PR3 or cathepsin G under the tested conditions. The claim is not extended to direct ELANE-mediated membrane lysis or to every symbiont species.

Summary: The study connects NET-associated proteolytic responses with measured bacterial killing.

Reason: Human neutrophils generate NETs after several stimuli; isolated NET preparations are proteolytically active, and a DNase-sensitive assay measures E. coli killing with phagocytosis blocked. ELANE-directed inhibition affects PMA-, Candida- and GBS-induced NET formation, but not the ionophore pathways, and GW311616A also inhibits PR3. Together with independently demonstrated ELANE histone proteolysis during NET formation, this supports a contextual contribution to neutrophil antibacterial activity. The bacterial-killing assay does not isolate the fraction of killing attributable specifically to ELANE.

Summary: ELANE can contribute to Gram-negative antibacterial defense through proteolytic peptide generation.

Reason: Human NE generates antibacterial thrombin-derived fragments, with activity against the reported Gram-negative organisms. This is catalytic participation in producing antimicrobial effectors rather than transfer of the peptides' membrane-disrupting chemistry to ELANE. The mouse Pseudomonas protection experiment administers a synthetic peptide, not an ELANE perturbation, and the neutrophil-extract preparation is not an ELANE-specific killing assay. The two raw interacting-taxon contexts remain preserved separately even though the normal source projection contains one assertion.

Summary: The specific fungal-killing inference remains unresolved despite positive Candida-induced NET formation.

Reason: The original shows ELANE-inhibitor-sensitive NET formation after Candida albicans stimulation. However, its directly measured killing assay uses tetracycline-resistant E. coli, including when Candida was the NET-inducing stimulus. The recovered main text, embedded supplemental captions and author response preserve this distinction. They support participation in the Candida-triggered NET response, but do not by themselves resolve the specific directed fungal-killing claim. The source-data workbooks and figure pixels have not been independently inspected here, and the broader fungal mechanism remains to be reconciled with other evidence. Retain uncertainty rather than assert that ELANE lacks antifungal activity or that the curator made a demonstrated error.

Summary: ELANE is localized to extracellular DNA structures in retrieved human thrombi.

Reason: The recovered original Methods identify an anti-neutrophil-elastase antibody and define NETs using extracellular DNA filaments associated with neutrophil granule proteins. Figure 3C explicitly describes elastase-positive extracellular DNA fibers. This supports the imported NET localization in human arterial thrombi. The original text and legend were read, but the image pixels and raw microscopy were not inspected; the study does not establish ELANE catalytic activity in those specimens or a causal contribution to stroke from localization alone.

Summary: ELANE is a component of neutrophil extracellular traps.

Reason: The exact mouse donor maps to Elane and has experimental NET localization support. PMID:32045782 includes endogenous human NE/DNA NET staining and mouse NET imaging; independent human work also places ELANE in released NET material. This compartment claim is distinct from its catalytic contribution to NET formation and does not imply a newly defined processed isoform.

Summary: ELANE performs histone cleavage that contributes to NET formation in the assayed contexts.

Reason: The source connects direct histone proteolysis and chromatin decondensation to stimulated human-neutrophil NET formation, with independent mouse infection/knockout context. This is participation through catalytic work, beyond a requirement inferred only from perturbation. GW311616A also inhibits PR3, and poorly responsive isolated mouse peritoneal cells are not recast as a genotype-specific PMA phenotype. The claim is bounded to the demonstrated pathways rather than universal NET dependence.

Summary: ELANE catalytic activity contributes to the measured NET-formation pathway.

Reason: Human-neutrophil experiments connect ELANE release and nuclear translocation with histone processing, while purified NE binds and degrades actin in a separate assay. These observations support proteolytic work during the tested PMA/Candida responses. ELANE is not assigned the MPO-dependent membrane-translocation activity: its catalytic inhibition does not prevent the release step, and that mechanism remains distinct from the downstream proteolysis.

Summary: ELANE contributes to stimulus-dependent NET formation rather than to every NET pathway.

Reason: The study measures NET formation in primary human neutrophils after PMA, Candida albicans, GBS or ionophore stimulation. GW311616A reduces the first three responses but not A23187- or nigericin-induced NET formation. The known PR3 overlap of this inhibitor limits enzyme-specific attribution from this experiment alone; independent direct ELANE histone-cleavage and chromatin-decondensation evidence supports the biological participation. Positive NET formation is retained with these stimulus and inhibitor boundaries.

Summary: ELANE contributes proteolytic work to NET formation.

Reason: The mouse donor supports NET formation in defined stimulation settings. PMID:32045782 combines human inhibitor/recombinant-enzyme experiments with mouse Elane knockout observations. Independent PMID:20974816 connects ELANE histone cleavage to chromatin decondensation and NET release, providing a mechanistic step beyond necessity alone. This does not require ELANE in every NET pathway or identify the experimental mature enzyme with the complete official precursor.

Summary: The rat source does not isolate ELANE-specific promotion of leukocyte rolling.

Reason: The exact rat donor identity is established, and PMID:20860667 reports reduced rolling after BbCI treatment during carrageenan inflammation. However, the study verifies inhibition of elastase, cathepsin G and cathepsin L; it does not isolate which protease accounts for the rolling phenotype. Broader genetic evidence for ELANE-dependent migration does not by itself resolve this more specific tethering/rolling claim. Preserve the source and positive observation while leaving the transferred gene-specific mechanism unresolved, rather than calling the result false.